This inventor holds 12 USPTO granted patents and 1 EPO patent. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Merck & Dohme Limited. Active years: 2000-2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Sawbridgeworth, GB (2000 - 2002)
- Harlow, GB (2003)
- Hertford, GB (2004 - 2010)
Company Filing History:
8 out of 2,405 
3 out of 4,770 
1 out of 1 Years Active: 2000-2010
Title: The Innovative Journey of Christopher Richard Moyes
Introduction
Christopher Richard Moyes, an accomplished inventor based in Sawbridgeworth, GB, has made significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 12 patents, Moyes is recognized for his groundbreaking research and development in chemokine receptor activity modulation. His innovative spirit and dedication have allowed him to push the boundaries of scientific understanding and therapeutic applications.
Latest Patents
One of Moyes' latest patents is focused on "Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity." This invention outlines compounds that are instrumental as modulators of the chemokine receptor CCR-2, showcasing their potential in treating various medical conditions. The patent also introduces crucial intermediates that facilitate the preparation of these innovative compounds.
Another significant patent is for "Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity." Similar to his previous work, this invention revolves around compounds designed to modulate CCR-2 receptor activity, further solidifying his expertise in this vital area of research.
Career Highlights
Christopher Richard Moyes has had a notable career, contributing to prestigious companies such as Merck Sharp & Dohme Corporation and Merck & Company, Inc. His work at these organizations has been pivotal in developing pharmacological solutions that have far-reaching implications for healthcare.
Collaborations
Throughout his career, Moyes has collaborated with prominent professionals in the field, including colleagues Michael Rowley and Lihu Yang. These partnerships have fostered a collaborative environment that has driven innovation and progress in the research of chemokine receptors and related therapies.
Conclusion
In summary, Christopher Richard Moyes stands out as a leading inventor in the realm of chemokine receptor activity modulation. His contributions, reflected in his multitude of patents, highlight an enduring commitment to improving health outcomes through scientific innovation. His work continues to inspire future generations of researchers and inventors in the pursuit of transformative solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile